A big step for MYC-targeted therapies

IF 14.3 1区 医学 Q1 ONCOLOGY Trends in cancer Pub Date : 2024-04-05 DOI:10.1016/j.trecan.2024.03.009
Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher
{"title":"A big step for MYC-targeted therapies","authors":"Danielle F. Atibalentja, Anja Deutzmann, Dean W. Felsher","doi":"10.1016/j.trecan.2024.03.009","DOIUrl":null,"url":null,"abstract":"<p>The <em>MYC</em> proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by <span>Garralda <em>et al.</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"8px\" viewbox=\"0 0 8 8\" width=\"8px\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg> of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"9 1","pages":""},"PeriodicalIF":14.3000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.03.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
向MYC靶向疗法迈出一大步
MYC 原癌基因编码一种主转录调节因子,在人类癌症中经常发生失调。数十年的努力都未能找到 MYC 靶向治疗药物,这仍然被认为是药物开发的圣杯。我们重点介绍 Garralda 等人最近关于 OMO-103 在实体瘤恶性肿瘤患者中的 1 期临床试验的报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Trends in cancer
Trends in cancer Medicine-Oncology
CiteScore
28.50
自引率
0.50%
发文量
138
期刊介绍: Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.
期刊最新文献
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation. A hormetic response model for glutamine stress in cancer. Functional heterogeneity of fibroblasts in primary tumors and metastases. Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency. Exercise against nonsmall-cell lung carcinoma: novel insights.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1